A certain type of drug called THR-β agonists might help improve both fatty liver and liver scarring in adults with MASLD, and it also seems to help with cholesterol and fats in the blood—making it a two-in-one treatment for liver and metabolism.

What we've found so far is that the evidence we've reviewed leans toward THR-β agonists having a positive effect on liver fat, scarring, and blood lipid levels in adults with MASLD [1]. Our analysis of the available research shows support across nearly 49 studies or assertions indicating these drugs may help improve both liver and metabolic health [1]. We looked at what the evidence says about THR-β agonists, a type of drug being studied for metabolic dysfunction-associated steatotic liver disease (MASLD). What we’ve seen so far suggests these drugs may reduce fat buildup in the liver and also improve signs of liver scarring, which is a more advanced form of liver damage [1]. In addition, the same evidence indicates improvements in cholesterol and other fats in the blood, such as triglycerides and LDL cholesterol—markers linked to heart and metabolic health [1]. It’s important to note that while the number of supporting assertions is high, we are reporting only what has been claimed across these analyses. We don’t know the exact study designs, sample sizes, or durations behind each assertion, so our current analysis reflects the direction of the evidence, not its strength or consistency. There are no studies or claims in this set that contradict the idea that THR-β agonists help with these outcomes [1]. Since our analysis is based on the available assertions and not primary data, we can’t say how large the effects are or how quickly they occur. Also, we don’t have information on side effects or long-term outcomes from this evidence alone. Practical takeaway: Based on what we’ve reviewed so far, THR-β agonists appear to be a promising option that might address both liver and cholesterol issues in people with MASLD—but more detailed, high-quality studies would help us better understand how much benefit to expect.